Pulse Biosciences (PLSE) Q2 2026 earnings review
Clinical Momentum Accelerates, But Dilution Follows
Pulse Biosciences is firing on all clinical cylinders, highlighted by the accelerated enrollment timeline for its NANOPULSE-AF pivotal study. However, the financial reality of a clinical-stage medtech company is setting in. Operating cash burn accelerated to $18.7 million in Q2, forcing the company to tap $46.8 million from its ATM facility. While insider participation ($13 million) in the capital raise is a strong signal of confidence, the company's nominal revenue of $434 thousand underscores that meaningful commercial cash flow is still years away. Investors must weigh the disruptive potential of the nsPFA platform against the certainty of ongoing capital needs.
🐂 Bull Case
The NANOPULSE-AF catheter study surpassed the halfway point. By amending the protocol to include patients on all four classes of anti-arrhythmic drugs, management expanded the addressable pool and reiterated completion by early Q4 2026—three months ahead of the original timeline.
Of the $46.8 million raised in the Q2 ATM offering, approximately $13 million came directly from insiders, indicating strong internal belief in the technology's clinical outcomes and regulatory path.
🐻 Bear Case
Operating cash burn jumped 46% YoY to $18.7 million in Q2. Despite holding $101.6 million in cash, the company immediately put a new $75 million ATM in place and maintains a $125 million shelf, signaling heavy future dilution.
Revenue remains nominal at $434 thousand. The 'controlled commercial launch' of the Vybrance system for soft tissue ablation requires establishing reimbursement and economic viability before scaling, effectively delaying meaningful revenue.
⚖️ Verdict: ⚪
Neutral. The clinical de-risking of the nsPFA platform is progressing faster than expected, but the financial burn rate is accelerating just as quickly. The technology is promising, but the investment requires a high tolerance for equity dilution.
Key Themes
NANOPULSE-AF Protocol Amendment Accelerates Timelines
The U.S. IDE pivotal study for the nPulse Cardiac Catheter System (NANOPULSE-AF) amended its protocol to allow patients who failed any of the four classes of anti-arrhythmic drugs (AADs), rather than a restricted subset. This change, reflecting real-world patient management, increased the evaluable target by 19 patients (to 164) while simultaneously enabling an earlier completion target of early Q4 2026.
Dilution Engine is Running
To fund its ambitious clinical pipeline, Pulse is heavily relying on ATM (at-the-market) equity sales. The company raised $46.8 million in Q2, plus an additional $10.7 million post-Q2. While necessary, the immediate establishment of a fresh $75 million ATM facility and an active $125 million shelf registration guarantees ongoing dilution for current shareholders as cash burn climbs.
Surgical and Soft Tissue Ablation Programs Advancing
The company's multi-pronged pipeline remains stable and on track. The NANOCLAMP-AF surgical pivotal study is enrolling toward a H1 2027 completion. Meanwhile, the PRECISE-BTN study for benign thyroid nodules expanded to 100 patients and is expected to complete enrollment 'within the month', achieving trial completion across three sites in under one year.
Commercial Partnership for Thyroid Nodules
Pulse announced a specific partnership with the Clayman Thyroid Center in Florida. This is a critical strategic move to validate the economic and clinical viability of the Vybrance system in a high-volume setting, which is a necessary precursor to broader commercialization and securing favorable reimbursement.
Other KPIs
Accelerating significantly from $12.1 million a year ago and $12.6 million in Q1 2026. This 40% YoY surge directly reflects the expanding clinical footprint across three active IDE studies and the associated compensation required to support these programs.
Reversing the downward trajectory seen over the past year. Cash was heavily replenished by $46.8 million in net ATM proceeds, masking the underlying $18.7 million quarterly operating burn. Post-quarter actions added another $12.5 million from ATM and warrant exercises.
Guidance
Accelerating. Management reiterated this target, which represents a three-month acceleration from original expectations, driven by protocol amendments that expanded the qualifying patient pool.
Stable. The company expects to finish enrolling the expanded 100-patient cohort in under one year, setting the stage for post-market data readouts to support commercialization efforts.
Stable. The U.S. IDE pivotal study for concomitant surgical AF ablation remains on its previously stated trajectory.
Key Questions
ATM Utilization Strategy
With the new $75 million ATM facility and $125 million shelf in place, what is the targeted cash runway, and how aggressive will the company be in tapping these facilities given the current $18.7 million quarterly burn?
Partnership Strategy Update
In prior quarters, management highlighted the pursuit of a strategic partnership with an EP market leader for the nPulse catheter. Does the accelerated clinical timeline shift the timing or leverage in these discussions?
Vybrance Reimbursement Timeline
With PRECISE-BTN finishing enrollment, what is the concrete timeline for securing a specific therapeutic indication from the FDA and establishing the reimbursement codes necessary for a broad launch?